TY - JOUR
T1 - Akt activation mediates acquired resistance to fibroblast growth factor receptor inhibitor BGJ398
AU - Datta, Jharna
AU - Damodaran, Senthilkumar
AU - Parks, Hannah
AU - Ocrainiciuc, Cristina
AU - Miya, Jharna
AU - Yu, Lianbo
AU - Gardner, Elijah P.
AU - Samorodnitsky, Eric
AU - Wing, Michele R.
AU - Bhatt, Darshna
AU - Hays, John
AU - Reeser, Julie W.
AU - Roychowdhury, Sameek
N1 - Publisher Copyright:
© 2017 American Association for Cancer Research.
PY - 2017/4
Y1 - 2017/4
N2 - Activation of FGFR signaling through mutations, amplifications, or fusions involving FGFR1, 2, 3, or 4 is seen in multiple tumors, including lung, bladder, and cholangiocarcinoma. Currently, several clinical trials are evaluating the role of novel FGFR inhibitors in solid tumors. As we move forward with FGFR inhibitors clinically, we anticipate the emergence of resistance with treatment. Consequently, we sought to study the mechanism(s) of acquired resistance to FGFR inhibitors using annotated cancer cell lines. We identified cancer cell lines that have activating mutations in FGFR1, 2, or 3 and treated them chronically with the selective FGFR inhibitor, BGJ398. We observed resistance to chronic BGJ398 exposure in DMS114 (small-cell lung cancer, FGFR1 amplification) and RT112 (urothelial carcinoma, FGFR3 fusion/amplification) cell lines based on viability assays. Reverse-phase protein array (RPPA) analysis showed increased phosphorylation of Akt (T308 and S473) and its downstream target GSK3 (S9 and S21) in both the resistant cell lines when compared with matching controls. Results of RPPA were confirmed using immunoblots. Consequently, the addition of an Akt inhibitor (GSK2141795) or siRNA was able to restore sensitivity to BGJ398 in resistant cell lines. These data suggest a role for Akt pathway in mediating acquired resistance to FGFR inhibition.
AB - Activation of FGFR signaling through mutations, amplifications, or fusions involving FGFR1, 2, 3, or 4 is seen in multiple tumors, including lung, bladder, and cholangiocarcinoma. Currently, several clinical trials are evaluating the role of novel FGFR inhibitors in solid tumors. As we move forward with FGFR inhibitors clinically, we anticipate the emergence of resistance with treatment. Consequently, we sought to study the mechanism(s) of acquired resistance to FGFR inhibitors using annotated cancer cell lines. We identified cancer cell lines that have activating mutations in FGFR1, 2, or 3 and treated them chronically with the selective FGFR inhibitor, BGJ398. We observed resistance to chronic BGJ398 exposure in DMS114 (small-cell lung cancer, FGFR1 amplification) and RT112 (urothelial carcinoma, FGFR3 fusion/amplification) cell lines based on viability assays. Reverse-phase protein array (RPPA) analysis showed increased phosphorylation of Akt (T308 and S473) and its downstream target GSK3 (S9 and S21) in both the resistant cell lines when compared with matching controls. Results of RPPA were confirmed using immunoblots. Consequently, the addition of an Akt inhibitor (GSK2141795) or siRNA was able to restore sensitivity to BGJ398 in resistant cell lines. These data suggest a role for Akt pathway in mediating acquired resistance to FGFR inhibition.
UR - http://www.scopus.com/inward/record.url?scp=85016937064&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85016937064&partnerID=8YFLogxK
U2 - 10.1158/1535-7163.MCT-15-1010
DO - 10.1158/1535-7163.MCT-15-1010
M3 - Article
C2 - 28255027
AN - SCOPUS:85016937064
SN - 1535-7163
VL - 16
SP - 614
EP - 624
JO - Molecular cancer therapeutics
JF - Molecular cancer therapeutics
IS - 4
ER -